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sensors located in the membrane of the endoplasmic reticulum. STIM and Orai proteins are expressed in vascular and airway smooth muscle and constitute the molecular components of the ubiquitous store-operated Ca 2ϩ entry pathway that mediate the Ca 2ϩ release-activated Ca 2ϩ current. STIM/Orai proteins also encode store-independent Ca 2ϩ entry pathways in smooth muscle. Altered expression and function of STIM/Orai proteins have been linked to vascular and airway pathologies, including restenosis, hypertension, and atopic asthma. In this review we discuss our current understanding of Orai proteins and the store-dependent and -independent signaling pathways mediated by these proteins in vascular and airway smooth muscle. We also discuss the current studies linking altered expression and function of Orai proteins with smooth muscle-related pathologies.
store-operated calcium entry; Orai; stromal-interacting molecule; calcium signaling; vascular and airway disease; smooth muscle remodeling SMOOTH MUSCLE REMODELING is a feature of many diseases, including restenosis, atherosclerosis, hypertension, and atopic asthma (10, 63) . This remodeling is initiated by various insults in the form of mechanical injury or inflammatory mediators. In response to these insults, smooth muscle cells (SMCs) undergo phenotypic modulation, altering their transcriptional profile from a quiescent contractile phenotype to a more synthetic phenotype, whereby SMCs proliferate, migrate, and deposit extracellular matrix (9, 60) . This phenotypic modulation is characterized by a remodeling of the repertoire of ion channels in smooth muscle (36) . Recently, SMCs have also been shown to act as immune effector cells that actively participate in the inflammatory response through production and secretion of various cytokines and inflammatory factors [e.g., transforming growth factor (TGF)-␤, interleukin (IL)-11, IL-6, and leukemia inhibitory factor], further exacerbating the disease (21) . These pathologically related phenotypic changes enhance and sustain vascular and airway remodeling and are the basis of various cardiovascular and respiratory diseases.
Alterations in Ca 2ϩ homeostasis directly regulate smooth muscle phenotypic modulation, and changes in protein expression of various Ca 2ϩ channel proteins have been shown to contribute to smooth muscle remodeling in vascular and respiratory diseases. Stromal-interacting molecule (STIM)/Orai family members are the molecular components of the storeoperated Ca 2ϩ entry (SOCE) pathway, as well as the storeindependent Ca 2ϩ entry pathway, in SMCs (6, 30, 67, 107, 108) . Deficiency in STIM1 or Orai1 expression is associated with immune deficiency, autoimmune disease, skeletal muscle hypotonia, and ectodermal dysplasia associated with sweat gland dysfunction and defects in development of tooth enamel (40) . Gain-of-function mutations in STIM1 and Orai1, resulting in constitutive unregulated Ca 2ϩ entry, which is associated with a number of diseases, including forms of myopathy, have been reported (40) . In smooth muscle, enhanced expression of STIM/Orai proteins is a feature of vascular and airway remodeling in animal models of mechanical balloon injury in vessels (30, 104, 106) and atopic asthma (81) . Upregulation of STIM/ Orai expression and enhanced Ca 2ϩ signals contribute to phenotypic modulation of vascular and airway SMCs (2, 6, 30, 31, 46, 81, 92, 104) . STIM/Orai-mediated Ca 2ϩ signaling pathways activate downstream effector proteins and transcription factors that promote SMC proliferation and migration (see below). In this review we discuss our current understanding of Ca 2ϩ entry pathways mediated by STIM/Orai proteins in SMCs and discuss the role of these Ca 2ϩ -selective channels in vascular and airway disease.
Orai Proteins in Smooth Muscle
Mammalian Orai proteins are a class of Ca 2ϩ -selective plasma membrane channel proteins made up of three homologs, Orai1, Orai2, and Orai3, encoded by three independent genes (77) . Invertebrates have one single Orai gene; all vertebrates possess two Orai genes, Orai1 and Orai2; the Orai3 gene is exclusive to mammals. Orai1 is expressed in human embryonic kidney (HEK-293) cells as two different isoforms: a long form, Orai1␣, containing an additional NH 2 -terminal 63 amino acids, and a short form, Orai1␤ (Fig. 1) . These Orai1 isoforms are the result of alternative translation-initiation sites within the Orai1 message; the long-form, Orai1␣, is exclusive to mammals (26) . mRNA of all three Orai homologs is ubiquitously expressed, including expression in vascular and airway SMCs from different species, including humans. Protein expression levels in contractile vascular SMCs obtained from human or rat aorta are negligible (5, 67) . However, in cultured aortic SMCs, which are reminiscent of synthetic dedifferentiated SMCs found in disease states, expression levels of STIM1, Orai1, Orai2, and Orai3 are dramatically increased (5, 6, 30, 67) . Expression levels of Orai1␣ and Orai1␤ have not been characterized in SMCs, but such studies are warranted, as these isoforms have been shown to have distinct signaling and regulatory properties (17) .
Orai1 contains four transmembrane domains (23) , with its NH 2 -and COOH-terminal domains residing in the cytosol (69) (Fig. 1) . The use of myc-tagged Orai1 at the NH 2 -or COOHterminal end confirmed Orai1 plasma membrane (PM) localization. In vascular SMCs, Orai1 colocalizes with the wellknown PM marker wheat germ agglutinin (6) . Similarly, when Orai2 and Orai3 proteins are ectopically expressed, they locate at the PM (32) -dependent inhibition (CDI) of Orai channels (blue lines) (56): 4 transmembrane-spanning domains, TMD1, TMD2, TMD3, and TMD4 (gray) with extracellular loops between TMD1 and TND2 and between TMD3 and TMD4. TMD1 and the first extracellular loop contain a highly conserved pore region with a conserved "E" residue (red) representing the selectivity filter. The intracellular loop contains residues 153-157, proposed to mediate fast Ca 2ϩ -dependent inhibition (blue line) (82) . The COOH-terminal region contains a coiled-coil domain, required for stromal-interacting molecule 1 (STIM1) binding and gating of Orai channels (pink). Orai1 contains a distinct proline-rich NH2-terminal domain (peach) from M1 to P17. The conserved CaMbinding domain (blue line) spans E68-R91. Orai1 contains a conserved CaM-binding domain (blue) spanning E68-R91. Orai1 also has 4 conserved transmembrane domains (TMD1, TMD2, TMD3, and TMD4), a conserved pore residue at E106 (red), and a distinct glycosylation site within the second extracellular loop at N223 (blue). The shorter form of Orai1 (Orai1␤) originates from an alternative initiation-translation of the Orai1 mRNA at methionine 63 (M63; blue) (17, 26) . Orai1 contains a region shown to mediate interaction with the Ca 2ϩ -sensitive adenylate cylase 8 (AC8; green line) (98) , which contains 2 serine residues (S27 and S30; green), which are targets for phosphorylation by protein kinase C (34) , and a putative caveolin-binding domain (purple line). Orai2, the smallest of the 3 isoforms, contains all conserved functional domains, with its CaM-binding domain spanning H42-R65, its pore-selectivity filter residue at E80, and its COOH-terminal coiled-coil domain spanning residues S221-Q252. The Orai3 CaM-binding domain spans residues Q43-R66; the homologous residue to E106 in Orai1 is E81. Orai3 contains a distinctly long extracellular loop (olive) between TMD3 and TMD4 and its COOHterminal coiled-coil domain spanning residues S269-V295. Conserved COOH-terminal glutamate residues (3 in Orai2/Orai3 and 2 in Orai1; dark blue) determine more enhanced fast Ca 2ϩ -dependent inactivation of Orai2/Orai3 than Orai1 (41) . ‫,ء‬ Conserved residues among all 3 Orai homologs; conserved residues between 2 Orai homologs.
brane domains, which are highly conserved among all Orai homologs. Between these transmembrane domains are two extracellular loops: the first is shorter, with a large number of acidic residues (69) made up of nine conserved amino acids, including a glutamate residue [E106 (Orai1), E80 (Orai2), and E81 (Orai3)], a glutamine residue [Q108 (Orai1), Q81 (Orai2), and Q83 (Orai3)], and within Orai1 three aspartate residues (D110, D112, and D114) (96) . Orai1:E106, in particular, and its homologs in Orai2 and Orai3 are critical for Ca 2ϩ selectivity of Orai channels (69, 94, 101) . Orai1 constructs where E106 was substituted for glutamine (E106Q) or alanine (E106A) yield a dead channel, and when E106 was mutated to a similar amino acid, aspartate (E106D), Orai1 channels lose their Ca 2ϩ selectivity and mediate monovalent and divalent cation currents equally (69, 101) , highlighting the importance of the size and charge of pore-forming domain structures in selectivity of this ion channel. The second extracellular loop, located between transmembrane domains 3 and 4, is much longer in Orai3 than in Orai1 or Orai2 (Fig. 1) .
The (82) showed that five residues spanning 153-157 (NVHNL) within the intracellular loop of Orai1 also participate in the fast Ca 2ϩ -dependent inactivation. Within STIM1, a string of acidic residues (475-483) that are COOHterminal to the STIM-Orai-activating region (SOAR; residues 344 -442) are required for mediation of CDI of Orai1 channels (16, 41, 56) . Furthermore, recent data from our laboratory showed much more pronounced CDI in Orai1␣ than Orai1␤ channels (17) ; however, the molecular basis of this difference and the 63 NH 2 -terminal residues within Orai1␣ that contribute to enhanced CDI remain unknown. Orai1 contains a distinct proline-and arginine-rich region in its NH 2 terminus (8) that binds much more weakly to STIM1 than does the COOHterminal region but was, nonetheless, proposed to regulate channel gating by STIM1 (102) . The NH 2 terminus contains a region involved in interaction with the Ca 2ϩ -sensitive adenylate cyclase 8 (98) and contains two protein kinase C phosphorylation sites (34) . A putative caveolin-binding domain is also located in the NH 2 terminus (Fig. 1) . The COOH-terminal domain of all three Orai homologs contains a conserved STIMbinding coiled-coil domain. The importance of this coiled-coil domain in gating Orai channels was first identified in Orai1 (25) . This COOH-terminal coiled-coil domain is essential for Orai1 channel activation by virtue of its role in mediating binding to STIM1. Upon store depletion, a 100-amino acid region in STIM1, SOAR, interacts with the COOH-terminal coiled-coil domain of Orai1 to activate the Orai1 channel (54, 55, 62, 102) . Within this COOH-terminal coiled-coil domain of Orai channels, Lee et al. (41) showed that three conserved glutamates in the COOH terminus of Orai2 and Orai3 (E233, E235, and E236 in Orai2; Fig. 1 ) mediate fast Ca 2ϩ -dependent inactivation, which is more prominent in Orai2 and Orai3 than in Orai1. Interestingly, Frischauf et al. (25) reported that COOH-terminal coiled-coil domain probability varies between Orai homologs, with the lowest probability observed for Orai1 and a five-to six-times-greater probability for Orai2 and Orai3 COOH-terminal coiled-coil regions; this suggests a correlation between this coiled-coil probability and the interactions between different Orai isoforms and STIM1. A single-residue mutation in the Orai1 coiled-coil region (L273S) disrupted the interaction of Orai1 with the STIM1 COOH-terminal domain, while equivalent mutations in Orai2 or Orai3 supported moderate interaction with STIM1 and channel activation. Reciprocally, decreasing coiled-coil probability of the second coiledcoil region in the COOH terminus of STIM1 by mutation of one residue (L373S) abrogated activation of Orai1 while allowing partial activation of Orai2 and Orai3 (25) .
SOCE in Smooth Muscle
Vascular smooth muscle. SOCE, a widespread means of regulated Ca 2ϩ entry into cells from the extracellular space, was first introduced by Putney (71) . PM receptors that couple to isoforms of phospholipase C (PLC) induce production of inositol 1,4,5-triphosphate (IP 3 ) (83) . IP 3 causes Ca 2ϩ release from the endoplasmic reticulum (ER) through the IP 3 receptor, and this ER Ca 2ϩ store depletion is the signal that triggers activation of PM store-operated Ca 2ϩ channels. SOCE can be activated pharmacologically by specific inhibitors of the sarco/endoplasmic reticulum Ca 2ϩ -ATPase (SERCA), such as thapsigargin and cyclopiazonic acid (CPA), which passively deplete internal Ca 2ϩ stores without producing second messengers (86) . The Ca 2ϩ current mediating SOCE, Ca 2ϩ release-activated Ca 2ϩ current (I CRAC ), was first identified in mast cells by whole cell patch-clamp recordings. I CRAC is activated when store depletion is achieved by inclusion of Ca 2ϩ chelators (alone or with IP 3 ) in the patch pipette; I CRAC is an inwardly rectifying Ca 2ϩ -selective current that has a reversal potential around ϩ60 mV and is voltage-insensitive (35) . After nearly two decades, STIM and Orai molecules were finally identified as the genuine molecular components of SOCE and I CRAC (70) . STIM and Orai proteins are also expressed in cells of the vasculature and mediate SOCE in endothelial cells and SMCs (1, 67, 75) . STIM proteins are single-pass transmembrane proteins located in the ER membrane with an NH 2 -terminal luminal lowaffinity EF-hand. STIM proteins sense Ca 2ϩ store depletion within the lumen of the ER, while Orai proteins are the store-operated Ca 2ϩ channels at the PM. ER Ca 2ϩ store depletion causes STIM molecules to accumulate at junctional ER-PM spaces, where they trap and gate Orai channels through physical interactions between the cytosolic COOH-terminal SOAR domain of STIM and the COOH-terminal coiled-coil domain of Orai; to interact with STIM, Orai channels diffuse to these regions of the PM closely associated with the ER.
The molecular identity of the PM SOCE channels in SMCs and in other cell types was a matter of intense debate over the past decades (for review see Ref. 68) . With the discovery of STIM and Orai proteins as the bona fide molecular components of SOCE in Drosophila Schneider 2 cells and in mammalian lymphocytes (70), Peel et al. (64, 65) used siRNA knockdown to document roles for STIM1 and Orai1 in mediating SOCE in cultured human airway SMCs. Our laboratory provided evidence for the existence of the highly Ca 2ϩ -selective store depletion-activated current I CRAC in cultured rat vascular cells as well as airway SMCs. We established a role for STIM1 and Orai1 in mediating SOCE and I CRAC in these cells in response to passive store depletion or agonist stimulation, namely, by the SMC proproliferative promigratory agonist platelet-derived growth factor (PDGF) (6, 67, 81) .
Studies from our laboratory used cultured proliferative migratory vascular SMCs (also referred to as synthetic cells), which represent a good in vitro model for dedifferentiated SMCs under pathophysiological conditions such as restenosis and atherosclerosis (60) . Passive store depletion in synthetic vascular SMCs activated Ca 2ϩ entry, which bears pharmacological features of the classical SOCE pathway, characterized in lymphocytes and HEK-293 cells (61) , including inhibition by 30 -50 M 2-aminoethoxydiphenyl borate (2-APB), 50 M ML-9, and relatively low concentrations (5 M) of lanthanides (93) . In the same study we showed that store depletion activated I CRAC in cultured synthetic vascular SMCs (67) . Knockdown of STIM1 or Orai1 inhibited SOCE and I CRAC in these cells, while knockdown of Orai2, Orai3, and the transient receptor potential (TRP)-canonical (TRPC) channels TRPC1, TRPC4, and TRPC6 had no effect on SOCE or I CRAC . These findings are supported by other studies in a number of mammalian cells where native SOCE is mediated by STIM1 and Orai1, despite ubiquitous protein expression of Orai2 and Orai3 in all these cells (90) . The only exception is a subset of estrogen receptor-positive breast cancer cells, where Orai3, along with STIM1, mediates SOCE (52, 53) . TRP channels, especially isoforms belonging to the TRPC subfamily, have long been proposed to mediate SOCE in many cell types, including those of the vasculature (SMCs and endothelial cells) (29, 91) . However, while there is evidence that certain isoforms of TRPC channels work closely and in concert with Orai channels, are regulated by STIM1 proteins, and fulfill nonoverlapping physiological roles (11, 13) , the general consensus is that TRPC channels are activated secondarily to store depletion by receptor-mediated mechanisms, including Orai1-generated Ca 2ϩ signals and lipid second messengers generated downstream from the PLC pathway (19) . SOCE measured by fura 2 imaging is upregulated in synthetic vascular SMCs compared with quiescent contractile SMCs, which were acutely isolated from vessels and studied within 6 h of isolation (67) . This enhanced SOCE in synthetic SMCs correlated with increased protein expression of STIM1 and Orai1 compared with levels of these proteins in freshly isolated quiescent vascular SMCs. Knockdown of STIM1 and Orai1 using siRNA attenuated proliferation and migration in synthetic vascular SMCs (67 entry; knockdown of Orai2, Orai3, and STIM2 had a marginal effect on PDGF-induced vascular SMC migration (6) . The PDGF receptor is upregulated in vascular occlusive disease and promotes vascular remodeling through initiation of SMC migration, proliferation, and extracellular matrix deposition, subsequently contributing to remodeling and neointimal hyperplasia (72). Ogawa et al. (59) showed that the PDGF-activated Akt/mammalian target of rapamycin pathway enhances SOCE and pulmonary artery SMC proliferation through upregulation of STIM1 and Orai1 expression. Inhibition of Akt reduced SOCE, proliferation, and STIM/Orai expression (59). Munoz et al. (57) showed that nonsteroidal anti-inflammatory drugs indirectly inhibit SOCE in A10 vascular SMCs by causing mitochondrial depolarization, thus inhibiting mitochondrial uptake of cytosolic Ca 2ϩ and causing cytosolic Ca 2ϩ -dependent inhibition of SOCE. This provides a potential mechanism by which nonsteroidal anti-inflammatory drugs inhibit vascular SMC proliferation, including proliferation of A10 SMCs as described by Munoz et al.
The vasoactive agonist urotensin II, which also promotes vascular SMC proliferation, enhanced Ca 2ϩ influx through a pathway pharmacologically reminiscent of SOCE in vascular SMCs (18, 73) . Under conditions where cytosolic Ca 2ϩ was buffered to 150 nM by high concentrations of a Ca 2ϩ chelator (10 mM BAPTA-5 mM CaCl 2 ), urotensin II activated whole cell currents in cultured aortic SMCs that were biophysically and pharmacologically reminiscent of I CRAC , including inward rectification and inhibition by 5 M Gd 3ϩ (73) . Interestingly, urotensin II-mediated Ca 2ϩ entry measured with fura 2 in these cultured aortic SMCs was dependent on TRPC1, in addition to STIM1 and Orai1 (73) . This likely reflects close interactions between STIM1/Orai1-mediated I CRAC and nonselective TRPC channels. The latter are likely activated secondarily to store depletion and Ca 2ϩ entry through Orai1 channels (e.g., direct activation by Ca 2ϩ or Ca 2ϩ -dependent delivery to the PM of TRPC-containing vesicles) (11, 12, 17, 91) . Consistent with this notion, coimmunoprecipitation experiments showed that urotensin II enhanced the STIM1-Orai1 and Orai1-TRPC1 interactions in cultured aortic SMCs (73) . Rodriguez-Moyano et al. (73) also showed that pharmacological inhibition of SOCE (by 50 M 2-APB or 10 M ML-9) significantly inhibited epidermal growth factor receptor and ERK phosphorylation in response to urotensin II. Reciprocally, pharmacological inhibition of epidermal growth factor receptor and ERK inhibited the Ca 2ϩ increase and proliferation of cultured aortic SMCs in response to urotensin II. Pharmacological inhibition of SOCE or knockdown of STIM1, Orai1, or TRPC1 inhibited urotensin II-mediated activation of the transcription factor cAMP response element-binding protein (CREB), suggesting a role for vascular SMC Ca 2ϩ signaling in CREB activation and cell proliferation (73) .
Despite the involvement of STIM1 and Orai1 in vascular SMC SOCE, the SOCE pathway has distinct pharmacological characteristics in vascular SMCs compared with other cell types that, potentially, could be exploited for selective drug targeting of vascular SOCE for the purpose of therapy. Earlier work from our laboratory showed that 2-APB fully inhibits rat aortic vascular SMC SOCE at concentrations 10-fold lower than those required to block SOCE in other cell types (67) . A subsequent study showed that the SOCE blocker S66 inhibits human saphenous vein SMC SOCE and cell migration at concentrations roughly two orders of magnitude lower than those required to block SOCE in other cell types (42) . While the molecular basis for this enhanced SOCE sensitivity to channel blockers in vascular SMCs remains unknown, these data suggest that Orai1 in vascular SMCs has high sensitivity for pharmacological compounds and could be selectively targeted without affecting other cell types, including leukocytes, where SOCE plays a prominent role in immune function and competence.
The characteristic sustained Ca 2ϩ signal that is mediated by SOCE regulates various Ca 2ϩ /CaM-dependent enzymes, including the serine/threonine phosphatase calcineurin (24) . In an agonist-dependent manner, calcineurin regulates transcriptional programs in vascular SMCs through activation of transcription factors, most notably isoforms of nuclear factor of activated T cells (NFAT). NFAT resides in the cytosol under basal conditions in a phosphorylated state; upon SOCE activation, NFAT is dephosphorylated by calcineurin, promoting its nuclear translocation, DNA binding, and transcriptional regulation of genes. NFAT-regulated genes are involved in various processes, including inflammation, proliferation, and migration (33) . In synthetic vascular SMCs, passive store depletion by thapsigargin or receptor stimulation by PDGF leads to the nuclear translocation of NFAT (47, 104, 106) . Knockdown of STIM1 or Orai1 expression prevents nuclear translocation of NFAT in vascular SMCs, with a corresponding decrease in promoter activity, as assessed by luciferase reporter assays (104) . Synthetic vascular SMCs downregulate expression of SERCA2a, which is abundantly expressed in contractile vascular SMCs (44) . Bobe et al. (7) reported that restoration of SERCA2a expression in synthetic human coronary artery SMCs by gene transfer altered the nature of agonist-induced Ca 2ϩ signaling from sustained to oscillatory, abrogated SOCE by inhibiting STIM1-Orai1 interactions, and inhibited NFAT nuclear translocation and SMC proliferation and migration, providing further evidence that sustained, robust Ca 2ϩ entry mediated by SOCE couples to NFAT and vascular SMC growth and remodeling.
Damage endured by the vessel in response to removal of the atherosclerotic plaque using a procedure called balloon angioplasty and stent insertion often leads to restenosis. Restenosis involves vessel remodeling, whereby vascular SMCs proliferate and migrate to the luminal side of the injured vessel, depositing excess matrix proteins and forming the neointimal layer, leading to recidivous occlusion of the vessel (60, 105) . The use of this mechanical vascular injury procedure in rat carotid arteries provides an in vivo model to study vascular SMC dedifferentiation during disease. STIM1 and Orai1 protein expression were upregulated in the medial and neointimal layers of balloon-injured rat carotid arteries (74, 104) . These injured vessels also showed an increase in vascular muscle proliferation compared with controls as assessed by increased expression of the proliferative markers Ki-67 and proliferating cell nuclear antigen in the SMCs. Infection of injured vessels with a lentivirus containing shRNA against STIM1 or Orai1 prevented Orai1 and STIM1 upregulation in the media and neointima, inhibited cell proliferation, and attenuated neointima formation (2, 104) . Subsequent studies confirming these earlier findings showed that knockdown of STIM1 and Orai1 inhibited angiotensin II-activated Ca 2ϩ entry and proliferation of synthetic vascular SMCs. Knockdown of STIM1 and Orai1 using siRNA inhibited neointimal growth induced by angiotensin II after vascular injury, suggesting a potential role for SOCE in angiotensin II-induced SMC proliferation during vascular disease (31).
STIM1 and Orai1 were implicated in the pathogenesis of arterial hypertension, whereby protein expression of Orai1 and STIM1 was increased in aortas derived from stroke-prone spontaneously hypertensive rats compared with wild-type Wistar-Kyoto rats. Store depletion caused a greater STIM1-and Orai1-dependent SOCE in arteries from hypertensive than normotensive rats. Giachini et al. (28) stimulated vessels with thapsigargin to activate SOCE and relied on nonspecific inhibitors such as 2-APB and Gd 3ϩ at high concentrations (100 M) to link SOCE function to enhanced vessel contraction in hypertensive rats. Nevertheless, enhanced SOCE in hypertensive rats might indeed account for enhanced receptor signaling through contractile mediators (e.g., phenylephrine and angiotensin II) (38, 47) . Notwithstanding an effect on contractility, STIM1/Orai1 and SOCE upregulation in vessels from hypertensive animals might suggest the establishment of SMC remodeling, which is a major contributor to the chronic phase of hypertension.
Mancarella et al. (47) generated SMC-specific STIM1 knockout (sm-STIM1-KO), STIM2 knockout (sm-STIM2-KO), and STIM1/STIM2 double-knockout mice. The doubleknockout mice were perinatally lethal, while sm-STIM1-KO mice exhibited high mortality and reduced body weight; sm-STIM2-KO mice did not show an obvious phenotype. The use of external potassium chloride to assess depolarization-induced contraction on aortas of sm-STIM1-KO mice showed normal contractility in these mice. However, ␣ 1 -adrenergic-mediated contraction of sm-STIM1-KO mice was inhibited by ϳ26%, suggesting a defect in contractile ␣ 1 -adrenergic signaling (47) . Consistent with previous results with rat balloon injury, neointima formation caused by carotid artery ligation was reduced by 54% in sm-STIM1-KO mice compared with littermate controls. Furthermore, in vascular SMCs isolated from sm-STIM1-KO mice and stimulated with PDGF, in vitro proliferation was strongly inhibited, while Ca 2ϩ entry and NFAT nuclear translocation were essentially abrogated (47) . A subsequent study from our laboratory generated sm-STIM1-KO mice, as well as endothelial-specific STIM1 knockout (ec-STIM1-KO) mice, and showed that body weight was reduced in sm-STIM1-KO and ec-STIM1-KO mice. Consistent with the results of Mancarella et al., we also showed that artery vessel contraction to ␣ 1 -adrenergic stimulation with phenylephrine was significantly reduced only in sm-STIM1-KO mice, while contraction to thromboxane A 2 agonist and potassium chloride was normal. Mancarella et al. showed that sm-STIM1-KO mice show abnormally developed vascular and intestinal smooth muscle tissues with distended and thinned morphology. Therefore, using siRNA, we acutely downregulated STIM1 in arteries ex vivo and showed that the contractile response to phenylephrine was inhibited, with no effect on contractility in response to thromboxane, suggesting that defects in contractile ␣ 1 -adrenergic signaling are not developmentally related (38) . An Ossabaw miniature swine model was used in an animal study to address the issue of accelerated coronary artery disease in areas adjacent to stenting (peri-stent) in metabolic disease. Animals fed an excess-calorie atherogenic diet (metabolic syndrome) show increased SOCE and coronary artery disease in non-and peri-stent segments of coronary arteries. Exercise reverses coronary artery disease and increases in SOCE, as well as STIM1, Orai1, and TRPC1 upregulation (20) .
Themes

C406 Orai CHANNELS IN SMOOTH MUSCLE
In an early study that predates the discovery of STIM and Orai proteins, Lin et al. (43) were the first to show upregulation of SOCE and diacylglycerol (DAG)-activated Ca 2ϩ entry in pulmonary artery SMCs during hypoxic pulmonary hypertension and correlated these enhanced Ca 2ϩ entry routes to increased expression of the TRPC isoforms TRPC1, TRPC3, and TRPC6 (TRPC3 and TRPC6 are receptor-activated channels gated by DAG). Ng et al. (58) subsequently proposed that interactions between TRPC1, Orai1, and STIM1 underlie SOCE induced by acute hypoxia in pulmonary artery SMCs. Wang et al. (97) proposed that peroxisome proliferator-activated receptor-␥ (PPAR␥) plays a protective role in pulmonary hypertension induced by chronic hypoxia. They proposed that PPAR␥ decreases proliferation and migration of pulmonary artery SMCs through inhibition of SOCE, which is upregulated by exposure to hypoxia. In the same study, they correlated their findings with expression of TRPC1 and TRPC6 proteins; however, STIM/Orai isoform expression was not addressed (97) . In a subsequent study, Yang et al. (100) suggested that enhanced SOCE in hypoxia-exposed pulmonary artery SMCs is mediated through the upregulation of caveolin-1, arguing that SOCE channels are organized within caveolin-rich regions. Molecular knockdown of caveolin-1 inhibited hypoxiamediated increases in SOCE, and the PPAR␥ agonist GW1929 reduced SOCE and caveolin-1 expression under hypoxic conditions (100).
Zhang et al. (103) reported that SOCE was increased in pulmonary artery SMCs from patients with idiopathic pulmonary hypertension (IPAH) compared with control normotensive patients. In a subsequent study, Song et al. (80) showed that STIM2 expression level was increased in pulmonary artery SMCs from IPAH patients, while STIM1 levels were decreased and knockdown of STIM2 in these cells inhibited SOCE and proliferation, while STIM2 knockdown in pulmonary artery SMCs from controls had no effect on SOCE or cell proliferation. Overexpression of STIM2 in control cells did not cause an increase in SOCE or proliferation, leading the authors to conclude that STIM2 plays a necessary, but not sufficient, role in upregulation of SOCE and enhanced pulmonary artery SMC proliferation during IPAH (80) . The failure of STIM2 overexpression to cause an increase in SOCE and proliferation in control cells is likely due to the fact that native Orai channel expression is limiting in control cells and that concurrent upregulation of different isoforms of Orai channels in IPAH is required for enhanced SOCE. Indeed, follow-up studies showed that STIM2 and Orai2 are upregulated in proliferating pulmonary artery SMCs compared with quiescent contractile cells, suggesting a role for STIM2/Orai2-mediated SOCE in phenotypic modulation and proliferation of pulmonary artery SMCs (22) .
A recent study by Daskoulidou et al. (15) described the upregulation of all STIM and Orai proteins by chronic treatment with high glucose (25 mM), which correlated with enhanced SOCE in response to store depletion in vascular endothelial cells. This upregulation could be prevented by cyclosporin A and knockdown of NFATc3, leading the authors to conclude that upregulation of STIM/Orai proteins by hyperglycemia is mediated by the calcineurin/NFAT pathway, which enhances SOCE and causes endothelial dysfunction (15) . The enhanced expression of STIM/Orai isoforms was also observed in aortas from diabetic patients and from two different animal models of diabetes (15 (65) to propose an additional role for Orai3 in regulating basal levels of ER Ca 2ϩ or in mediating Ca 2ϩ release from internal stores. The allergen-induced mucosal injury characteristic of asthmatic airways is believed to initiate a repair cascade that involves secretion of growth factors, including PDGF, which stimulate airway SMCs (95) . In whole cell patch-clamp recordings, PDGF activated a small inwardly rectifying Ca 2ϩ current characteristic of I CRAC that could be further amplified by the use of divalent free bath solutions in rat airway SMCs (81) . Knockdown of Orai1 expression in synthetic rat airway SMCs inhibited PDGF-mediated activation of SOCE and I CRAC and attenuated airway SMC proliferation and migration (81) . Using chemotaxis chamber assays, Suganuma et al. (84) investigated the role of STIM1 and Orai1 in PDGF-mediated human airway SMC migration. They showed that PDGF-activated Ca 2ϩ entry and migration in these cells were significantly reduced by siRNA against STIM1 or Orai1, confirming the potential role for SOCE in human airway SMC remodeling; in this study, knockdown of STIM2 with siRNA had no effect on SOCE or cell migration (84). Zou et al. (109) showed that, similar to synthetic vascular SMCs, SOCE and STIM1/Orai1 expression were enhanced during airway SMC proliferation. Pharmacological blockade of SOCE using the inhibitors SKF-96365 (10 M) and BTP2 (100 nM) or molecular knockdown of STIM1 or Orai1 inhibited SOCE and reduced airway SMC proliferation in response to serum (109). Gao et al. (27) suggested that TGF␤1 (10 ng/ml) induced an increase in expression of STIM1 and Orai1 in airway SMCs with enhancement of basal cytosolic Ca 2ϩ levels and SOCE in response to thapsigargin. They reported that rat airway SMC proliferation in response to serum and TGF␤1 was partly reduced by 10 M SKF-96365 (27). Jia et al. (37) showed that IL-13 and TNF␣ enhance puncta formation of ectopically expressed fluorescently tagged STIM1 and increased SOCE in airway SMCs, suggesting that inflammatory cytokines might contribute to airway hyperresponsiveness through increased SOCE in human airway SMCs during disease.
While airway SMC hyperresponsiveness to contractile agonists is a hallmark of asthmatic airways, airway SMC pheno-typic modulation involving proliferation and hypertrophy is also a major contributor to the pathophysiology of asthma and other airway obstructive diseases (14, 66) . Patients with severe asthma tend to have an increase in airway smooth muscle mass and enhanced distance between airway smooth muscle and luminal epithelium, suggesting increased airway SMC proliferation, hypertrophy, and rate of migration (66) . STIM1 and Orai1 proteins are upregulated in airway SMCs from asthmatic mice, suggesting a potential role for SOCE in the pathogenesis of atopic asthma (81) . However, the specific role of STIM and Orai proteins in asthma development and airway SMC remodeling has not been examined. In addition to this role in promoting the airway SMC synthetic proliferative phenotype, SOCE signaling has been proposed to play a role in regulating Ca 2ϩ signals that mediate airway SMC contraction. Based on the use of 3-fluoropyridine-4-carboxylic acid, a nonspecific pharmacological blocker of SOCE in guinea pig airway SMCs, Sutovska et al. (85) proposed that G protein-coupled receptor agonists such as histamine regulate airway SMC contractility through activation of the SOCE pathway. However, extensive studies are required to clarify the role of SOCE in airway SMC contractility. Wylam et al. (99) incubated human airway SMCs with cigarette smoke extract and showed enhanced SOCE and increased expression of Orai1 and STIM1. Knockdown of Orai1 inhibited the effects of cigarette smoke extract on SOCE. These authors also reported that cigarette smoke extract enhanced proliferation of airway SMCs and, thus, concluded that enhanced expression of Ca 2ϩ signaling proteins such as Orai1 and STIM1 and subsequent increase in SOCE activity could play a role in the pathogenesis of airway disease in smokers (99) .
Store-Independent Ca 2ϩ Entry in Smooth Muscle
STIM and Orai proteins also encode a different receptormediated Ca 2ϩ entry pathway that is store-independent (74, 79) . This store-independent pathway is activated by receptormediated production of arachidonic acid (AA) or its metabolite leukotriene C 4 (LTC 4 ) (30, 49, 76) , and the conductance it mediates was originally characterized in HEK-293 cells and termed AA-regulated Ca 2ϩ current (I ARC ) (48) . I ARC and I CRAC are not additive in the same cell, suggesting that these two conductances are mediated by physically distinct channels (48) . I ARC is biophysically similar to I CRAC , and both pathways often co-exist in the same cells, suggesting that they control distinct cellular and physiological functions. I ARC has some unique features: it has a less pronounced Ca 2ϩ -dependent fast inactivation under a voltage-step protocol, and it is not inhibited by high concentrations (50 M) of 2-APB or by reductions in external pH (78) .
Production of AA or its downstream metabolite LTC 4 after receptor ligation can occur through a range of enzymatic pathways, including 1) direct generation of AA from membrane glycerophospholipids by the action of the phospholipase A 2 family of enzymes or 2) from sequential catalytic activities of PLC on phosphatidylinositol 4,5-bisphosphate (which generates DAG) and DAG lipase action on DAG, which will yield AA, and 3) through the activity of phosphatidic acid phosphohydrolase on phosphatidic acid produced through phospholipase D (78) . Nevertheless, I ARC was predominantly studied by addition of relatively low concentrations (8 M) of exogenous AA to the bath solution, which causes activation of Ca 2ϩ entry and membrane currents without measurable depletion of internal Ca 2ϩ stores. Using HEK-293 cells, Shuttleworth and colleagues (50, 51, 87) showed that I ARC required STIM1, Orai1, and Orai3 and proposed that the minor pool of STIM1 expressed at the plasma membrane is involved in the activation of I ARC while the NH 2 -terminal domain of Orai3 determines the selectivity for activation by AA over store depletion.
Vascular smooth muscle. Studies from our laboratory showed that the mitogenic and inflammatory agonist thrombin activates store-independent Ca 2ϩ entry and membrane currents in cultured rat aortic SMCs that were additive to SOCE and I CRAC activated by PDGF (30) . Maximal concentrations of thrombin do not cause sustained store depletion, and blockade of IP 3 receptor-mediated Ca 2ϩ release through dialysis of heparin in the patch pipette failed to inhibit thrombin-activated currents (30) . Thrombin-activated currents were highly Ca 2ϩ -selective currents, similar to I CRAC . However, they displayed some unique features that were distinct from I CRAC , as they did not show the typical phenomenon of depotentiation in divalent free solutions (whereby large Na ϩ currents through I CRAC are activated but immediately inactivate) and were not inhibited by 50 M 2-APB. Using molecular knockdown, we showed that this store-independent thrombin-activated Ca 2ϩ entry pathway requires Orai1, Orai3, and STIM1, with the pool of STIM1 that is restricted to the ER being necessary and sufficient (107) . Activation of this Ca 2ϩ entry route requires receptor-mediated production of AA through the actions of PLC and DAG lipase and AA metabolism into LTC 4 by the action of LTC 4 synthase (LTC 4 S) (30, 106) . Interestingly, exogenous AA added to the bath solution is metabolized by cells into LTC 4 for optimal channel activation; dialysis of LTC 4 through the patch pipette activated similar currents that were not additive to thrombin-or AA-activated currents (30) . We showed that the STIM1 COOH-terminal coiled-coil domain is constitutively interacting with store-independent Orai1/Orai3 heteromultimeric channels through the Orai3 COOH terminus and that this interaction is required for channel activation by LTC 4 in vascular SMCs (107) . We thus named this conductance LTC 4 regulated Ca 2ϩ current (I LRC ) (30) . In a follow-up study, we set out to establish whether I ARC in HEK-293 cells and I LRC in vascular SMCs are encoded by the same or different pools of STIM1, Orai1, and Orai3 proteins. We undertook comparative whole cell patch-clamp recordings of I ARC (activated by exogenous application of 8 M AA) and I LRC (activated by dialysis of 100 nM LTC 4 through the patch pipette) in HEK-293 cells and vascular SMCs and discovered that, regardless of cell type, I ARC and I LRC are not additive and require STIM1, Orai1, and Orai3, strongly arguing that these two currents are mediated by the same channel. Regardless of cell type (HEK-293 cells or vascular SMCs), a nonmetabolizable form of AA, 5,8,11,14-eicosatetraenoic acid, activated ϳ50% of the current activated by AA. Similarly, when exogenous AA was added to cells treated with a 5-lipoxygenase inhibitor to prevent AA downstream metabolism, only ϳ50% of the current densities were obtained compared with currents activated by dialysis of LTC 4 into the cytosol of cells treated with the 5-lipoxygenase inhibitor (108) . These data strongly argue that while AA is capable of activating these store-independent channels, AA metabolism into LTC 4 is required for full or optimal activation. We also addressed the discrepancy between data on HEK-293 cells from Thompson and Shuttleworth (88) and our own data on vascular SMCs (30) regarding the requirement of PM-STIM1 for I ARC vs. the requirement of ER-STIM1 for I LRC (108) . We found that when whole cell patch-clamp recordings were used in both cell types, a construct expressing STIM1 at the ER and PM was required for current activation by LTC 4 or AA. However, exclusive expression of STIM1 at the ER was sufficient to mediate current activation by LTC 4 or AA when the perforated patch-clamp technique or fura 2 Ca 2ϩ imaging was used. We concluded in this study that a soluble factor might be involved in interacting with the STIM1-Orai1-Orai3 complex and required for store-independent Orai1/Orai3 channel activation by LTC 4 ; this factor would be mostly dialyzed out when whole cell patch-clamp recordings are considered, but PM-STIM1 would help maintain its interaction with the channel complex. However, in the case of an intact cytosol, the soluble factor would be retained in the cytosol and the PM-STIM1 requirement would be bypassed (89) .
Orai channel heteromultimerization and store-independent Orai channel activation likely represent means to enhance the diversity of receptor- was rescued when vessels were infected with lentiviral particles encoding shRNA against LTC 4 S or Orai3 (106) . In a recent work, we used mouse embryonic fibroblasts isolated from Orai1 knockout mice and HEK-293 cells where endogenous Orai1 expression was silenced by siRNA (17) . In each case, Orai1 expression was restored with the use of cDNA plasmids that exclusively express Orai1␣ or Orai1␤ driven by a weak promoter to recapitulate the low physiologically relevant levels of Orai1 expression and prevent the dominantnegative effects associated with Orai1 overexpression (17) . We discovered that I CRAC could be recapitulated with Orai1␣ or Orai1␤, while I ARC /I LRC requires the long exclusively mammalian isoform Orai1␣ (17) . Although it is expected that I ARC /I LRC in vascular SMCs would also require Orai1␣, this specific experiment remains to be performed. Thompson et al. (89) showed that siRNA knockdown of STIM1 and Orai3 inhibited the amplitude and frequency of AA-activated Ca 2ϩ oscillations in human airway SMCs. Interestingly, similar results were obtained when caveolin-1 was knocked down with siRNA, suggesting that these channels are located within caveolin-rich regions of the PM (89); it is noteworthy that the long isoform of Orai1, Orai1␣, uniquely involved in store-independent Orai1/Orai3 channels, contains a caveolin-binding region in the 63 NH 2 -terminal amino acids that are lacking in Orai1␤ (17, 26) (Fig. 1) . Thompson et al. analyzed airway SMCs obtained from asthmatic patients and showed enhanced amplitude of AA-activated Ca 2ϩ oscillations compared with controls (89), suggesting a role for this pathway in asthma pathology. Clearly, extensive whole cell electrophysiological recordings are warranted to define this AA-activated Ca 2ϩ entry in airway SMCs. Furthermore, the specific downstream signaling mechanisms controlled by AA-activated Ca 2ϩ oscillations in asthmatic airway SMCs and their contributions to manifestations of asthma are important issues that warrant additional investigations.
Concluding Remarks
In general, Orai-mediated store-dependent and -independent Ca 2ϩ entry pathways (Fig. 2) , which are activated by a variety of growth, migratory, and inflammatory agonists, are upregulated during phenotypic modulation of vascular and airway smooth muscle associated with vascular and airway pathophysiologies. In animal models of disease, when in vivo upregulation of these molecules is prevented, SMC dedifferentiation and remodeling are inhibited. This causal link between Orai channel function and disease is of major interest in the development of agents that target Orai-mediated pathways in prevention and treatment of vascular occlusive disease and airway obstructive disease. For example, the effective antiproliferative agent sirolimus (rapamycin), which is clinically used in drugeluting stents to prevent postoperative vascular remodeling, has been shown to prevent proliferation of human coronary artery SMCs, at least in part through inhibition of the SOCE pathway and downstream CREB-mediated proliferative signaling (39) . Novel drugs targeting specific isoforms of Orai, especially the exclusively mammalian Orai3 proteins or the heteromultimeric store-independent Orai1␣/Orai3 channels, hold the promise of specific targeting of smooth muscle remodeling with limited side effects.
